Patents by Inventor Lbachir Benmohamed

Lbachir Benmohamed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250108108
    Abstract: A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.
    Type: Application
    Filed: December 9, 2024
    Publication date: April 3, 2025
    Inventor: Lbachir BenMohamed
  • Publication number: 20240269266
    Abstract: Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-?+TNF?+CD4+ and CD69+IFN-?+TNF?+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.
    Type: Application
    Filed: March 11, 2024
    Publication date: August 15, 2024
    Inventor: Lbachir BenMohamed
  • Publication number: 20230226173
    Abstract: Pan-coronavirus recombinant vaccine compositions featuring whole proteins or sequences of proteins encompassing all mutations in variants of human and animal Coronaviruses (e.g., 36 mutations in spike protein) or a combination of mutated B cell epitopes, mutated combination of B cell epitopes, mutated CD4+ T cell epitopes, and mutated CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The mutated epitopes may comprise one or more mutations. The present invention also describes using several immuno-informatics and sequence alignment approaches to identify several human B cell, CD4+ and CD8+ T cell epitopes that are highly mutated. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of human and animal Coronaviruses mutations.
    Type: Application
    Filed: October 13, 2022
    Publication date: July 20, 2023
    Inventor: Lbachir BenMohamed
  • Publication number: 20230173060
    Abstract: Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CD8 T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
    Type: Application
    Filed: October 14, 2022
    Publication date: June 8, 2023
    Inventor: Lbachir BenMohamed
  • Publication number: 20230146932
    Abstract: Multi-epitope, pan-coronavirus recombinant vaccine compositions featuring a combination of highly conserved B cell epitopes, highly conserved CD4+ T cell epitopes, and highly conserved CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The present invention uses several immuno-informatics and sequence alignment approaches and multiple immunological assays in vitro using human blood and saliva samples from COVID patients and healthy patients to identify several human B cells, CD4+ and CD8+ T cell epitopes that are highly conserved and antigenic in vitro. The Invention also used an in vivo unique mouse model of ACE2/HLA-A0201/HLA-DR triple transgenic mouse model to test the immunogenicity and the protective efficacy against SARS-CoV-2 infection and COVID-Like symptoms, of the identified B and T cell epitopes and of the resulting multi-epitope-pan-Coronavirus vaccine candidates.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 11, 2023
    Inventor: Lbachir BenMohamed
  • Patent number: 11213582
    Abstract: The present invention relates to compositions comprising HSV antigens and methods for their use in the treatment or prevention of asymptomatic and symptomatic herpesvirus infection, or recurrence.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: January 4, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Lbachir BenMohamed
  • Publication number: 20200046827
    Abstract: The present invention relates to compositions comprising HSV antigens and methods for their use in the treatment or prevention of asymptomatic and symptomatic herpesvirus infection, or recurrence.
    Type: Application
    Filed: August 8, 2019
    Publication date: February 13, 2020
    Inventor: Lbachir BenMohamed
  • Patent number: 9878033
    Abstract: Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of NLLTTPKFT and RMLGDVMAV and methods for administering such compositions to a mammal and thereby inducing in the mammal a CD8+ T cell-dependent protective immunity against an HSV-1 infection, an HSV-2 infection, an HSV-1 condition, an HSV-2 condition, or combinations thereof.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: January 30, 2018
    Assignee: The Regents of the University of California
    Inventors: Lbachir BenMohamed, Anthony Nesburn
  • Publication number: 20170065713
    Abstract: Certain embodiments of the present invention provide immunogenic compositions that comprise one or more peptides having an amino acid sequence selected from the group consisting of NLLTTPKFT and RMLGDVMAV and methods for administering such compositions to a mammal and thereby inducing in the mammal a CD8+ T cell-dependent protective immunity against an HSV-1 infection, an HSV-2 infection, an HSV-1 condition, an HSV-2 condition, or combinations thereof.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 9, 2017
    Applicant: The Regents of the University of California
    Inventors: Lbachir BenMohamed, Anthony Nesburn
  • Publication number: 20080299140
    Abstract: Immunogenic composition comprising at least one Herpes Simplex Virus type 1 (HSV-1) and/or type 2 (HSV-2) peptide sequence hearing at least one epitope from glycoprotein D (gD) and/or glycoprotein B (gB), a pharmaceutical carrier and/or a human compatible adjuvant, peptide sequences and uses thereof for prevention or treatment of an HSV condition.
    Type: Application
    Filed: May 23, 2003
    Publication date: December 4, 2008
    Applicant: The Regents of the University of California,
    Inventors: Bertrand Georges, Helene Gras-Masse, Lbachir BenMohamed, Anthony B. Nesburn
  • Publication number: 20060280752
    Abstract: Described herein are peptide epitopes effective in the treatment of herpes simplex virus (HSV), as well as vaccines and other therapeutic compositions including the same. In various embodiments, the compositions of the present invention may include a pharmaceutically acceptable adjuvant to enhance the delivery and/or pharmacological efficacy of the epitope. Also described are methods for treating and preventing HSV with the aforementioned epitopes, such as by administering a vaccine including the same. Other methods describe the use of the TEPITOPE algorithm to identify epitopes that may be useful in the treatment of HSV and related or unrelated disease conditions.
    Type: Application
    Filed: January 19, 2005
    Publication date: December 14, 2006
    Inventors: Lbachir BenMohamed, Anthony Nesburn
  • Publication number: 20030219448
    Abstract: Described herein are peptide epitopes effective in the treatment of herpes simplex virus (HSV), as well as vaccines and other therapeutic compositions including the same. In various embodiments, the compositions of the present invention may include a pharmaceutically acceptable adjuvant to enhance the delivery and/or pharmacological efficacy of the epitope. Also described are methods for treating and preventing HSV with the aforementioned epitopes, such as by administering a vaccine including the same. Other methods describe the use of the TEPITOPE algorithm to identify epitopes that may be useful in the treatment of HSV and related or unrelated disease conditions.
    Type: Application
    Filed: August 6, 2002
    Publication date: November 27, 2003
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Lbachir BenMohamed, Anthony B. Nesburn
  • Publication number: 20030166542
    Abstract: A lipopeptide, compositions containing the lipopeptide, and methods of inducing an immune response by administering the lipopeptide to a mucosal membrane of a subject.
    Type: Application
    Filed: June 5, 2002
    Publication date: September 4, 2003
    Applicant: INSTITUT PASTEUR
    Inventors: Pierre Druilhe, Helene Grasmasse, Lbachir Benmohamed
  • Publication number: 20030049267
    Abstract: A method of inducing an immune response by applying an immune response inducing effective amount of a lipopeptide to a mucosal membrane of a subject.
    Type: Application
    Filed: July 29, 2002
    Publication date: March 13, 2003
    Applicant: INSTITUT PASTEUR
    Inventors: Pierre Druilhe, Helene Gras-Masse, Lbachir Benmohamed